European weight-loss drug developers have staged something of a comeback this week, as investors rotate into healthcare from AI-exposed momentum stocks.
Zealand Pharma A/S shares have surged 20% since Monday, posting their biggest weekly advance since March 2024 and outperforming the pan-European Stoxx 600 index this week. Novo Nordisk A/S has advanced 6.8%, while Gubra A/S is up 18%. All three are still down by at least 28% this year.